Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 1, 2006

Hardcover (Print)
Buy New
Buy New from
Used and New from Other Sellers
Used and New from Other Sellers
from $4.50
Usually ships in 1-2 business days
(Save 97%)
Other sellers (Hardcover)
  • All (11) from $4.50   
  • New (5) from $41.00   
  • Used (6) from $4.50   


Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Read More Show Less

Editorial Reviews

Doody's Review Service
Reviewer: Michael Joel Schrift, DO, MA (University of Illinois at Chicago College of Medicine)
Description: This is a new series focusing on recent clinical trial results. After reading the book and perusing the website, it is unclear to me if this is a book, a peer-reviewed journal, or both. The editor states in the preface, "chapters are solicited continuously and placed online after editing. Online, these chapters are in the complete published and citable format. Annually, chapters are collected into a single volume and published in a book form. (This book.) On the web site, the section "Instructions for Contributors" states "Instructions for contributors not available." Whether this is a book or journal is important, in my opinion, from a research ethics point of view: books do not have to meet the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by the International Committee of Medical Journal Editors, which pertain to authorship and contributorship, editorship, peer review, conflicts of interest, privacy and confidentiality, and the protection of human subjects and animals in research. If this is a book with chapters on recent clinical trials and the chapters are treated as if they are manuscripts submitted to a biomedical journal, that would be a significant addition to the scientific literature. If the chapters in the book are not treated as if they are submissions to a journal, then I'm not sure how to judge this book. Nevertheless, this is written and edited by an array of internationally recognized clinician-researchers and has the promise of a significant contribution to psychiatry and neurology."
Purpose: The purpose of this series is to provide "updates of recent clinical trial results, impacts of trials on guidelines and evidenced-based practice, advances in trial methodologies, and the evolution of biomarkers in trials."
Audience: The intended audience includes "practicing neurologists, as well as clinical and translational neuroscientists." Psychiatrists and neuropsychiatrists would also be part of the audience, especially since several of the authors are psychiatrists.
Features: Areas covered include such topics as rivastigamine for dementia in Parkinson disease, minocycline for ALS, liquid fluoxetine for repetitive behaviors in autism, and selegeline for negative symptoms of schizophrenia. Each chapter (study) contains references that pertain to the study. There is a useful subject index at the back of the book as well as an author index. This publication needs to be proofread! For example, in the introductory chapter by the editor, Dr. Cummings, on page 4 it states: "Medical proficiency training program (MPTP) is used to create models for some aspects of parkinsonism." I think Dr. Cummings meant 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine.
Assessment: This is a new journal, book, or both — the publisher and editor need to clarify what this is. It is potentially a significant contribution to the neurotherapeutic literature, but without the needed clarifications, I cannot assess its relevance.
From the Publisher
"Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed."
Read More Show Less

Product Details

  • ISBN-13: 9780521862530
  • Publisher: Cambridge University Press
  • Publication date: 10/1/2007
  • Pages: 184
  • Product dimensions: 6.85 (w) x 9.72 (h) x 0.51 (d)

Meet the Author

Jeffrey L. Cummings, MD, is currently Director of both the Deane F. Johnson Center for Neurotherapeutics at UCLA, and the UCLA Alzheimer's Disease Center. He holds the Augustus Rose Professor of Neurology chair, was the Shrinavasan Lecturer in 2004 and the Henderson Lecturer in 2005.

Read More Show Less

Table of Contents

Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Terms of Use.
  • - Barnes & reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)